Generated by AI
Precision BioSciences, Inc. is a clinical-stage gene editing company focused on developing in vivo therapies for serious diseases with limited treatment options. Its proprietary ARCUS® genome editing platform is designed to make precise changes to DNA and supports programs aimed at treating chronic hepatitis B, Duchenne muscular dystrophy, and other high-unmet-need conditions. The company’s current work centers on advancing therapeutic candidates through clinical development, with an emphasis on direct gene correction, elimination, or insertion in targeted tissues. Precision BioSciences serves the biotechnology and life sciences markets by applying its editing technology to human therapeutics, positioning itself as a specialist in next-generation genetic medicine from its headquarters in Durham, North Carolina.
Website302 East Pettigrew St.
Durham, NC, 27701
United States
The latest articles about DTIL.
2026-11-13. The following slide deck was published by Precision BioSciences, Inc.
Summary of Nov 9's posts. Generated by AI.
Summary of Jun 25's posts. Generated by AI.
Summary of Mar 9's posts. Generated by AI.
Investors talking about DTIL also mention these. Each card shows that asset’s own numbers for the past 24 hours.
Valuation and earnings.